Kinase overexpressing cancers responsive to drug withdrawal.
作者信息
Amin Amit Dipak, Rajan Soumya S, Schatz Jonathan H
机构信息
Department of Medicine, Division of Hematology-Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Sheila and David Fuente Graduate Program in Cancer Biology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
出版信息
Aging (Albany NY). 2015 Oct;7(10):752-3. doi: 10.18632/aging.100830.
Abstract
摘要
相似文献
1
Kinase overexpressing cancers responsive to drug withdrawal.对药物撤药有反应的激酶过表达癌症。
Aging (Albany NY). 2015 Oct;7(10):752-3. doi: 10.18632/aging.100830.
2
BRAF inhibitors: the current and the future.BRAF抑制剂：现状与未来。
Curr Opin Pharmacol. 2015 Aug;23:68-73. doi: 10.1016/j.coph.2015.05.015. Epub 2015 Jun 10.
3
MEK inhibitors beyond monotherapy: current and future development.MEK抑制剂的联合治疗：现状与未来发展
Curr Opin Pharmacol. 2015 Aug;23:61-7. doi: 10.1016/j.coph.2015.05.012. Epub 2015 Jun 7.
4
CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.CH5424802，一种选择性的 ALK 抑制剂，能够阻断耐药性的守门员突变体。
Cancer Cell. 2011 May 17;19(5):679-90. doi: 10.1016/j.ccr.2011.04.004.
5
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.PF-06463922，一种ALK/ROS1抑制剂，在临床前模型中克服了对第一代和第二代ALK抑制剂的耐药性。
Cancer Cell. 2015 Jul 13;28(1):70-81. doi: 10.1016/j.ccell.2015.05.010. Epub 2015 Jul 2.
6
[Kinases and phosphatases: key enzymes in targeted cancer therapy].
Dtsch Med Wochenschr. 2013 Mar;138(9):437-40. doi: 10.1055/s-0032-1332885. Epub 2013 Feb 19.
7
BRAF inhibitors in cancer therapy.BRAF 抑制剂在癌症治疗中的应用。
Pharmacol Ther. 2014 May;142(2):176-82. doi: 10.1016/j.pharmthera.2013.11.011. Epub 2013 Dec 8.
8
Gatekeeper mutations mediate resistance to BRAF-targeted therapies.守门基因突变介导对 BRAF 靶向治疗的耐药性。
Sci Transl Med. 2010 Jun 9;2(35):35ra41. doi: 10.1126/scitranslmed.3000758.
9
Disease progression in some cancers may be due to low blood levels of targeted therapies.某些癌症的疾病进展可能是由于靶向治疗的血液水平较低。
J Natl Cancer Inst. 2008 Jul 2;100(13):912-3. doi: 10.1093/jnci/djn230. Epub 2008 Jun 24.
10
Inhibitors of the anaplastic lymphoma kinase.间变性淋巴瘤激酶抑制剂。
Expert Opin Investig Drugs. 2012 Jul;21(7):985-94. doi: 10.1517/13543784.2012.690031. Epub 2012 May 22.
本文引用的文献
1
Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors.有证据表明，间断给予ALK激酶抑制剂可能会延长对ALK阳性肿瘤的控制时间。
Cancer Res. 2015 Jul 15;75(14):2916-27. doi: 10.1158/0008-5472.CAN-14-3437. Epub 2015 May 27.
2
Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia.急性淋巴细胞白血病中的信号阈值与B细胞阴性选择
Nature. 2015 May 21;521(7552):357-61. doi: 10.1038/nature14231. Epub 2015 Mar 23.
3
Response to chemotherapy, reexposure to crizotinib and treatment with a novel ALK inhibitor in a patient with acquired crizotinib resistance.一名获得性克唑替尼耐药患者对化疗的反应、再次暴露于克唑替尼以及使用新型ALK抑制剂进行治疗
Respiration. 2014;88(3):262-4. doi: 10.1159/000364949. Epub 2014 Aug 7.
4
Response to crizotinib rechallenge after initial progression and intervening chemotherapy in ALK lung cancer.间变性淋巴瘤激酶（ALK）阳性肺癌初始进展及介入化疗后对克唑替尼再激发治疗的反应
J Thorac Oncol. 2013 Mar;8(3):e21. doi: 10.1097/JTO.0b013e31827a892c.
5
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.在黑色素瘤中建立vemurafenib 耐药模型揭示了一种预防耐药的策略。
Nature. 2013 Feb 14;494(7436):251-5. doi: 10.1038/nature11814. Epub 2013 Jan 9.
6
Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer.药代动力学过程和不同给药方案对表皮生长因子受体突变型肺癌患者获得性厄洛替尼耐药动力学的影响。
J Thorac Oncol. 2012 Oct;7(10):1583-93. doi: 10.1097/JTO.0b013e31826146ee.
7
NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases.NPM-ALK：致癌性融合酪氨酸激酶家族的原型成员。
J Signal Transduct. 2012;2012:123253. doi: 10.1155/2012/123253. Epub 2012 Jul 18.
Zotero 插件